Journal
HAEMATOLOGICA
Volume 92, Issue 8, Pages 1149-1150Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.11228
Keywords
cyclophosphamide; velcade and dexamethasone (CVD); comparable toxicity; high response rates
Categories
Ask authors/readers for more resources
The combination of bortezomib (velcade), pulsed dexamethasone and weekly cyclophosphamide (CVD) in relapsed/refractory myeloma patients induces high overall (75%) and complete (31%) response rates compared to velcade/dexamethasone (overall 47%, CR 5%) and velcade alone (overall 27%, CR 0%). The toxicity profiles including thrombocytopenia, neutropenia, and neuropathy were comparable between the groups.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available